Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919900 | 0.85 | VCAM1 (0.60) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL8960247 | 0.85 | POLB (0.53) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL6038596 | 0.84 | POLB (0.52) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL3906545 | 0.84 | POLB (0.52) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL540736 | 0.84 | POLB (0.52) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL12727381 | 0.83 | POLB (0.51) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| Hydrochloric Acid SCHEMBL27447923 | 0.83 | POLB (0.51) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| Water SCHEMBL3157352 | 0.83 | POLB (0.51) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL11091009 | 0.81 | POLB (0.60) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 | |
| SCHEMBL14519881 | 0.81 | POLB (0.50) | POLBMCOLN3ALDH1A1MAPK1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260021103-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250188470-A1 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| CN-120129676-A | Compounds, compositions, and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114746095-B | HCK as therapeutic target of MYD88 mutant diseases | 达纳-法伯癌症研究所有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250002637-A1 | OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR, AND RECYCLE | CONAGEN INC. (US) | 2025-01-02 | — | — | US | disclosed |
| CN-119212707-A | Oxadiazole HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118973616-A | Trkb ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| CN-106459162-A | VAR2CSA-drug conjugates | 酵活有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| CN-105358174-A | Cytotoxic and antimitotic compounds and methods of use thereof | CT FOR DRUG RES AND DEV | 2016-02-24 | — | — | CN | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021103-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | IKZF1, CSNK1A1, CKS1B | POLB 3824/4885MCOLN3 4414/4885ALDH1A1 3051/4885 |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | POLB 4738/4885MCOLN3 1231/4885ALDH1A1 2902/4885 |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | POLB 2231/4885MCOLN3 4143/4885ALDH1A1 527/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | POLB 303/4885MCOLN3 2781/4885ALDH1A1 2218/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | POLB 242/4885MCOLN3 1796/4885ALDH1A1 3393/4885 |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, MCL1 | POLB 2668/4885MCOLN3 3355/4885ALDH1A1 3887/4885 |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, CCNB2 | POLB 255/4885MCOLN3 1976/4885ALDH1A1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.